The app provides treatment options that consider the genetics of patients’ tumors. Treatment options include published clinical treatment guidelines and “beyond standard of care” medical and scientific evidence-based options. The treatment guidelines were developed by CollabRx’s 75-member advisory network, comprised of physicians, scientists and researchers.
“CancerRx was developed to serve as a trusted clinical decision support tool for physicians to quickly and efficiently translate clinical research advances into practical information that can be routinely used to inform cancer treatment planning at the point of care,” said Thomas Mika, chairman, president and CEO of CollabRx, in a news release.
More Articles on mHealth Apps:
BBK Worldwide Unveils 2 New Apps for Clinical Trial Patient Engagement
4 Recently Launched mHealth Apps
On Apple’s Heels, Google Introduces Health, Fitness Tracking Platform
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
